|
Oct 5
|
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
|
|
Oct 4
|
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
|
|
Oct 4
|
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
|
Oct 4
|
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
|
|
Oct 4
|
What end of Eli Lilly's weight-loss drug shortage means for the competition
|
|
Oct 4
|
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
|
|
Oct 4
|
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
|
|
Oct 4
|
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
|
|
Oct 4
|
NHS proposes phased launch for Eli Lilly’s Mounjaro
|
|
Oct 4
|
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
|
|
Oct 4
|
Top T. Rowe Price Fund Manager Shares Her Secrets
|
|
Oct 4
|
Texas sues major PBMs, pharma companies over high insulin prices
|
|
Oct 4
|
Ozempic for all, Zepbound is back, and the top CEO pay: Pharma news roundup
|
|
Oct 3
|
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
|
|
Oct 3
|
Top Research Reports for Exxon Mobil, Mastercard and Procter & Gamble
|
|
Oct 3
|
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
|
|
Oct 3
|
For Hims & Hers Stock, GLP-1 Giveth and GLP-1 Taketh Away
|
|
Oct 3
|
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
|
|
Oct 3
|
Update: Eli Lilly, CVS Among Companies Facing Lawsuit Over Inflated Insulin Prices
|
|
Oct 3
|
Sector Update: Health Care Stocks Softer Thursday Afternoon
|